Pharmacovigilance / Other

((A-232)) (A-232) High-throughput screening using self-controlled tree-based scan statistics to identify medications potentially associated with hospitalization for severe acute liver injury

((A-233)) (A-233) Overview of Post-Authorization Safety Studies Required by EMA for Products Approved in 2022

((A-234)) (A-234) Regional Differences in Tramadol Safety Reports: A Global Pharmacovigilance Analysis

((A-235)) (A-235) Evaluation of Effectiveness of Additional Risk Minimisation Measures (aRMMs): perspectives from a UK non-interventional post authorisation safety study (PASS)

((A-237)) (A-237) Age and multimodal safety assessments: limitations of spontaneous reports data and the importance of advancing age-based risk stratification capabilities in real world data

((A-238)) (A-238) Enhancing Post-marketing Quantitative Signal Detection at GSK: A Comprehensive Review

((A-239)) (A-239) Risk-Based Stratification of Pharmacovigilance Data for a Differentiated Approach to Follow-Up

((A-240)) (A-240) Enhancing The Meaningfulness of Qualitative Adverse Event Report Reviews Through Incorporation of Quantitative and Qualitative Aspects of Causality Assessment

((A-241)) (A-241) Safety Reporting of Homeopathic Products: A Preliminary Investigation in the FDA Adverse Event Reporting System (FAERS) Data

((A-242)) (A-242) Minoxidil-Induced Ocular Disorders: A Global Pharmacovigilance Analysis

((A-243)) (A-243) Ethambutol Under Scrutiny: Surge in Serious Eye Disorders

((A-244)) (A-244) Drug-Drug Interactions between Nirmatrilvir-Ritonavir and Cardiovascular Agents: A Scoping Review

((A-245)) (A-245) Safety and Effectiveness of B/F/TAF for the Treatment of HIV-1 Infection in a Large Cohort in South Korea: A Post-marketing Surveillance Study

((A-247)) (A-247) Evaluation of Companies Pharmacovigilance Systems:Measuring Performance Before and After Exposure to Saudi regulatory PV Inspection Visits

((A-248)) (A-248) Critical Vs Major finding; According to the classification of MAH in Saudi Arabia

((A-249)) (A-249) Establishing a repository for background incidence rates of adverse events for use in safety signal assessment

((A-251)) (A-251) Safety signal monitoring of an anti-COVID-19 drug in the MID-NET® in Japan

((A-252)) (A-252) Incidence of Outcomes Relevant to Vaccine Safety Monitoring in a General Population, After Influenza Vaccination, and After Respiratory Infections in US Claims Data from August 1, 2022 to July 31, 2023

((A-253)) (A-253) Determining Cardiovascular Safety Signals of Non-Steroidal Anti-Inflammatory Drugs: A Sequence Symmetry Study

((A-254)) (A-254) An Open Source Pipeline for Collaboration and Evaluation of Power in Tree-Based Scan Statistics Used in Pharmacovigilance

((A-255)) (A-255) Medication Use Evaluations for Medication Safety Profile and Risk Minimization Measures Assessment: a National Multicenter Study

((A-256)) (A-256) Identifying Potential Drug Triggers for Bullous Pemphigoid: A Disproportionality Analysis of the FDA Adverse Event Reporting System and Review of Case Reports

((A-257)) (A-257) Antimuscarinic Medication Use and Risk of Glaucoma: A Literature Review and Disproportionality Analysis Using FAERS

((A-258)) (A-258) Trimethoprim-Sulfamethoxazole (TMP-SMX) and Risk of Hemophagocytic Lymphohistiocytosis (HLH): A Literature Review and Disproportionality Analysis Using Individual Safety Case Reports from FAERS

((A-259)) (A-259) Ocular Adverse Effects of Zoledronic Acid: A Case Report of Partial Vision Loss and Literature Review.

((A-260)) (A-260) Safety of Moderna’s Omicron-Containing Bivalent and XBB1.5- containing Monovalent Vaccines: Results from a US Claims Database Cohort Study

((A-261)) (A-261) Anaphylaxis Risk Across Cephalosporin Generations and Cefaclor: Insights from a Nationwide Case-Crossover Study (2011–2023)

((A-262)) (A-262) A Case of Periocular/Palpebral Allergic Reaction due to Bepotastine Besilate Ophthalmic solution

((A-263)) (A-263) A Two-Year Review of Adverse Drug Events (ADEs) in Saudi Arabia: Trends and Pharmacovigilance Insights from 2023-2024

((A-264)) (A-264) A Proposed Framework to Leverage TreeScan Methods in Real-World Data for Signal Detection

((A-265)) (A-265) Assessing Study Feasibility Using Trends in the FDA PMR/PMC Database: 2020-2024

((A-266)) (A-266) Feasibility Assessment of Using National Administrative Databases (SISPRO) to Support Post-Authorization Vaccine Safety Studies in Colombia

((A-267)) (A-267) Using Machine Learning to Predict Classification of Causal and Non-causal Pharmacovigilance Cases

((A-268)) (A-268) Disproportionality analysis of sexual dysfunction reports related to integrase strand-transfer inhibitors: data from the FDA Adverse Reporting System - FAERS

((A-269)) (A-269) Disproportionality analysis of reports of HIV resistance to integrase strand-transfer inhibitors from the WHO global safety database

((A-270)) (A-270) A Collaboration to Explore and Compare Existing Tools for Retrieving Pregnancy Reports from VigiBase

((A-271)) (A-271) Postmarketing Requirements for Accelerated Approvals: An Analysis of Status, Therapeutic Areas, and Regulatory Designations

((A-272)) (A-272) Enhancing Safety Monitoring in Pharmacoepidemiology through High-Quality, Industry-Specific Translation Technology

((A-273)) (A-273) A Ten-year Record Analysis of Acute Poisoning in a Tertiary Hospital, Nigeria

((A-274)) (A-274) Characteristics of Drug Safety Alerts issued by two Latin American Drug Regulatory Agencies

((A-275)) (A-275) Monitoring Incidence of Acute Pancreatitis Following COVID-19 Vaccination compared with Background Incidence in Korea

((A-276)) (A-276) Regional trends of opioid epidemic using safety signal of drug misuse and dependence: a disproportionality analysis using Vigibase

((A-277)) (A-277) The Role of Pharmacovigilance Databases in Identifying Antibiotic Resistance and Inappropriate Use

((C-188)) (C-188) Completeness of Spontaneously Reported Adverse Drug Reactions in Four Developed Countries.

((C-189)) (C-189) Amnesia Associated with Teriparatide Use: Signal Review